Business Context and Reporting Period
This Form 8-K Current Report from Harvard Bioscience, Inc. covers the results of the 2023 Annual Meeting of Stockholders held on May 15, 2023. The filing details the voting outcomes for four proposals submitted to shareholders, including director elections, auditor ratification, and executive compensation advisory votes.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a report on corporate governance voting results.
Material Changes
There are no material financial changes reported in this document. The primary events are the successful election of directors and the ratification of the independent auditor.
Guidance, Outlook, and Voting Results
The filing reports the following outcomes from the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected two Class II Directors for a three-year term ending in 2026.
- Katherine A. Eade: 24,519,192 votes For; 2,616,295 votes Withheld.
- Thomas W. Loewald: 25,564,902 votes For; 1,570,585 votes Withheld.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes For: 33,325,418
- Votes Against: 9,580
- Votes Abstained: 61,387
- Proposal 3 (Say-on-Pay): Stockholders approved the compensation of Named Executive Officers via a non-binding advisory vote.
- Votes For: 26,568,836
- Votes Against: 531,708
- Votes Abstained: 34,943
- Proposal 4 (Say-on-Pay Frequency): Stockholders recommended an annual (one-year) frequency for future advisory votes on executive compensation.
- Votes For 1 Year: 25,372,472
- Votes For 3 Years: 1,498,941
- Votes For 2 Years: 24,073
Based on these results, the Board of Directors determined that future advisory votes on executive compensation will be held annually.
Key Facts for Investor Verification
- Verify the tenure of the newly elected directors (Katherine A. Eade and Thomas W. Loewald) through 2026.
- Confirm that Grant Thornton LLP is the appointed auditor for the fiscal year ending December 31, 2023.
- Note that the company has committed to annual "Say-on-Pay" votes following the shareholder recommendation.
- Review the Definitive Proxy Statement filed on April 5, 2023, for detailed background on the proposals.